Thousands of people around the world die every day from overdoses involving opioids such as fentanyl. Drugs that target opioid receptors sometimes have severe side effects. An international team of researchers has taken a closer look at the molecular mechanisms of these active substances. The research, carried out by Dr Matthias Elgeti, a biophysicist at Leipzig University, in collaboration with research groups from the US and China, has now been published in the journal Nature.
Opioid receptors are of great pharmacological interest because opioid substances regulate the perception of pain. “Our findings provide insights into how an opioid receptor can perform different functions. It is able to reduce pain, but also to regulate digestion or breathing,” explains Dr Elgeti, co-first author of the study from the Institute for Drug Discovery at the Faculty of Medicine.
In the current study, the biophysicist collaborated with international scientists, including the research group of Nobel laureate Brian Kobilka from Stanford University. They discovered that superagonists, such as fentanyl, stabilise a state of the receptor that causes particularly effective and long-lasting signal transmission. This means that superagonists are particularly potent and therefore dangerous. In the current study, the researchers used electron spin resonance and single-molecule fluorescence spectroscopy to determine different states of the opioid receptor and the structural effects of different binding partners.
Opioid receptors are members of the large family of G protein-coupled receptors (GPCRs), which control many signalling processes in the body, such as taste and smell, while others bind neurotransmitters and hormones or are activated by light. Understanding the molecular interactions of these receptors with drugs and other signalling proteins is very important for drug development. As all GPCRs are structurally very similar, the researchers hope that their findings on the opioid receptor can be applied to other receptors.
“This study involved isolating the opioid receptors. They are normally found in the body’s cells, interacting with many other proteins and molecules. Further research into the molecular interactions is therefore needed to gain a full understanding of the regulatory mechanisms,” says Dr Elgeti. The new study is an important building block in basic research, with further studies needed to ultimately develop better and safer medicines.
Translation: Matthew Rockey
Dr Matthias Elgeti
Institute for Drug Discovery
Faculty of Medicine, Leipzig University
Tel.: +49341/97-15774
matthias.elgeti@medizin.uni-leipzig.de
Original publication in Nature: Ligand efficacy modulates conformational dynamics of the µ-opioid receptor. DOI: 10.1038/s41586-024-07295-2, https://www.nature.com/articles/s41586-024-07295-2
Dr. Matthias Elgeti
Anton Stolle
Leipzig University
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler
Biologie, Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).